Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NRT Harm Reduction Indications Need Fast-Track Evaluation – Experts

This article was originally published in The Tan Sheet

Executive Summary

FDA should expedite moving NRT claims from a smoking cessation to a harm reduction framework, experts and stakeholders say. At a public hearing, the agency examined expanded indications for the drugs and the challenges FDA faces with two centers that intersect in the tobacco and cessation space.


Related Content

Tobacco Investment Means E-Cigarette Growth, But Drug Path Raises Questions
FDA Delves Into Broader Smoking Cessation Approach





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts